Brief: Mannkind On June 26, Was Informed Co's Contract Manufacturer Of Clofazimine Inhalation Solution Experienced Fire In Its Manufacturing Unit, Germany
03/07/2023 11:20
July 3 (Reuters) - MannKind Corp MNKD.O :
* MANNKIND - ON JUNE 26, WAS INFORMED CO'S CONTRACT
MANUFACTURER
OF CLOFAZIMINE INHALATION SOLUTION EXPERIENCED FIRE IN ITS
MANUFACTURING UNIT, GERMANY
* MANNKIND CORP-AS A RESULT OF INCIDENT, CO ESTIMATES
PRODUCTION
OF CLINICAL SUPPLIES OF MNKD-101 WILL BE DELAYED BY 3-6 MONTHS
* MANNKIND CORP-DELAY IN PRODUCTION HAS POTENTIAL TO IMPACT
INITIATION OF PHASE 2/3 CLINICAL STUDY OF MNKD-101 PLANNED FOR
LATER IN 2023
* MANNKIND CORP- EVALUATING SEVERAL MITIGATION STRATEGIES,
WILL
UPDATE PROJECTED TIMING FOR THE CLINICAL STUDY AT A LATER DATE
Further company coverage: MNKD.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children